Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + apatinib + capecitabine
- Development stage
- Unknown
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is a multi-agent regimen being investigated for the treatment of **esophageal cancer**. It consists of four distinct pharmacological components: **iparomlimab** (a PD-1 monoclonal antibody), **tuvonralimab** (a PD-1/CTLA-4 bispecific antibody), **apatinib** (a small molecule VEGFR2 tyrosine kinase inhibitor), and **capecitabine** (a cytotoxic fluoropyrimidine carbamate). The regimen aims to achieve synergistic anti-tumor effects by combining dual immune checkpoint blockade (targeting PD-1 and CTLA-4) to enhance T-cell mediated immunity, anti-angiogenic therapy to disrupt tumor vascularization, and antimetabolite chemotherapy to inhibit DNA synthesis. This specific combination is notably associated with clinical research conducted by **Taizhou People's Hospital**, where these agents are being evaluated to improve outcomes in patients with advanced esophageal squamous cell carcinoma.
- Brand names
- AnniweiKaitanniAiRuiKa
- Other names
- penpulimab + cadonilimab + apatinib + capecitabine
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + apatinib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + apatinib + capecitabine.